Navigation Links
Anti-inflammatory drugs reduce the risk of oral cancer for smokers,,

For light to medium smokers, daily intake of non-steroidal anti-inflammatory drugs (NSAID) may reduce the risk of having oral cancer.//

Norwegian scientists, who had conducted the studies, had said that people who took NSAIDs for extended time period have 65% less chance of having oral cancer than others, when both the groups are moderate smokers of tobacco. The study suggested that NSAID might have anti carcinogenic effect on smokers who smoked for 30 or less pack-years.

A pack-year is smoking for one year at a cigarette pack a day. Smokers smoking for 30 pack-years may be all those who have smoked a pack a day for 30 years, or two pack a day for fifteen years, or three packs a day for ten years.

The study was conducted by taking people from both Norway and US. Of the 908 participants of the study, about half of them was diagnosed having squamous cell carcinoma of the oral cavity, a sign of oral cancer.

The NSAIDs used for the study were aspirin, ibuprofen, naproxene, indomethacine, piroxicame, and ketoprofene. All of them were effective in reducing the risk of oral cancer. There was no significant association between acetaminophen or paracetamol, a non-aspirin pain relief medication and risk of oral cancer.


'"/>




Page: 1

Related medicine news :

1. Protein Secreted By Worm Eggs Holds Key To Anti-inflammatory Therapy
2. Anti-inflammatory Drug Fails to Improve COPD Symptoms
3. Cancer drugs in development nearly doubled since 1995
4. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
5. African HIV strains more resistant to anti HIV drugs
6. Right drugs drastically cut stroke risk
7. Relating heart protection and antihypertensive drugs
8. Enzyme may be target for obesity drugs
9. New HIV cases resist drugs
10. Relief to pregnant women using fertility drugs
11. AIDS drugs linked to heart attack risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have been diagnosed ... surgery, treatment, therapy and management. Regular exercise in proper environments has been shown ... their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic HydroWorx ...
(Date:2/21/2017)... NJ (PRWEB) , ... February 21, 2017 , ... ... research and conference coverage in veterinary medicine, will be launching its first bi-monthly ... animal health and medicine, business and practice management, and One Health. , ...
(Date:2/21/2017)... ... 2017 , ... Atlanta-based Jvion, the leading cognitive clinical science ... practice. Predixion, which raised $42M+ to date, received $20M in its third ... Ventures, and Software AG , will bring top industry talent and an impressive ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on Healio ... It found that the treatments have led to significant improvements in weight loss and ... efforts. It also noted very few problematic results relating to the treatment. Beverly Hills ...
(Date:2/20/2017)... Ill. (PRWEB) , ... February 20, 2017 , ... ... to reduce the rate at which women are called back for additional examinations ... journal Radiology . , In 2011, the U.S. Food and Drug Administration ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... MELBOURNE, Australia , Feb. 21, 2017  IBM (NYSE: ... IBM Watson,s ability to detect abnormalities of the eye,s retina. ... trained a research version of Watson to recognize abnormalities in ... insights and speed in their early identification of patients who ... glaucoma, a leading cause of blindness in the developed world. ...
(Date:2/21/2017)... Medical Oxygen Concentrators Market: Overview ... Medical oxygen concentrators are used by patients ... having low level of oxygen in their blood ... are to be used only with prescription and ... concentrators work either on rechargeable lithium batteries or ...
(Date:2/21/2017)...   BeyondSpring Pharmaceuticals , a clinical stage ... immuno-oncology cancer therapies, today announced that the Company,s ... 2 trial of BeyondSpring,s innovative lead asset, ... lung cancer (NSCLC) with Docetaxel has been selected ... Immuno-Oncology Symposium in Orlando, Fla. ...
Breaking Medicine Technology: